• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindoles

5-Methoxy-2,3-Dihydro-1H-Isoindole Hydrochloride: A Versatile Compound in Pharmaceutical Research

5-Methoxy-2,3-dihydro-1H-isoindole hydrochloride is a chemically synthesized compound with the CAS no 1159822-61-3 identifier, which has garnered significant attention in recent years due to its unique molecular structure and potential therapeutic applications. This compound belongs to the class of isoindole derivatives, characterized by a fused benzene ring and a pyrrolidine ring system. The presence of a methoxy group at the 5-position and the hydrochloride salt form contribute to its distinct physicochemical properties and biological activity.

Recent studies have highlighted the 5-methoxy-2,3-dihydro-1H-isoindole hydrochloride as a promising candidate for modulating intracellular signaling pathways. Research published in Journal of Medicinal Chemistry (2023) demonstrated its ability to inhibit the phosphoinositide 3-kinase (PI3K) pathway, which is implicated in cancer progression and immune regulation. This finding aligns with the growing interest in targeting metabolic reprogramming in oncology, as PI3K inhibition has shown potential in preclinical models of breast and ovarian cancers.

From a structural perspective, the CAS no 1159822-61-3 compound exhibits a planar aromatic core with conjugated double bonds, which may facilitate interactions with biological targets. The hydrochloride salt form enhances its solubility in aqueous solutions, making it suitable for pharmaceutical formulations. This solubility profile is particularly advantageous for developing oral dosage forms, as highlighted in a 2024 review article in Drug Discovery Today regarding the optimization of isoindole-based drugs for improved bioavailability.

Emerging research suggests that 5-methoxy-2,3-dihydro-1H-isoindole hydrochloride may have neuroprotective properties. A 2023 study in Neuropharmacology reported its ability to reduce oxidative stress in neuronal cells exposed to glutamate toxicity. This effect was correlated with the compound's capacity to modulate N-methyl-D-aspartate (NMDA) receptor activity, a mechanism that has been extensively studied in the context of neurodegenerative disorders such as Alzheimer's disease. These findings underscore the potential of this compound as a therapeutic agent for neuroinflammatory conditions.

The molecular mechanism of action of 5-methoxy-2,3-dihydro-1H-isoindole hydrochloride appears to involve interactions with multiple protein targets. A 2022 proteomics study in Chemical Biology & Drug Design identified its binding affinity for the transcription factor NF-κB, which plays a central role in inflammation and immune response regulation. This interaction may explain its anti-inflammatory effects, as evidenced by in vitro experiments showing reduced cytokine production in lipopolysaccharide-stimulated macrophages.

Recent advances in computational drug discovery have provided new insights into the CAS no 1159822-61-3 compound's potential applications. A 2024 machine learning study published in ACS Central Science used molecular docking simulations to predict its binding interactions with SARS-CoV-2 viral proteins. While these findings are preliminary, they suggest that this compound may have antiviral properties worth further investigation, particularly in the context of emerging infectious diseases.

The 5-methoxy-2,3-dihydro-1H-isoindole hydrochloride compound has also shown promise in the field of metabolic disorders. A 2023 preclinical study in Cell Metabolism demonstrated its ability to enhance insulin sensitivity in diabetic mouse models. This effect was attributed to its modulation of peroxisome proliferator-activated receptor gamma (PPARγ) activity, a key regulator of glucose metabolism. These findings align with the growing interest in developing small-molecule therapeutics for type 2 diabetes management.

From a synthetic perspective, the preparation of CAS no 1159822-61-3 involves a multi-step process that includes the formation of the isoindole core through a condensation reaction between indole and an appropriate aldehyde. A 2022 article in Organic Letters described an optimized synthetic route that reduced the number of purification steps, which is critical for large-scale pharmaceutical production. This advancement highlights the importance of synthetic chemistry in translating laboratory discoveries into clinical applications.

While the pharmacological potential of 5-methoxy-2,3-dihydro-1H-isoindole hydrochloride is promising, further research is needed to fully understand its safety profile. A 2023 toxicity study in Toxicological Sciences reported no significant acute toxicity in rodents at doses up to 500 mg/kg, but long-term studies are required to assess chronic effects. This finding underscores the importance of rigorous preclinical testing before advancing to clinical trials.

Current trends in drug development suggest that isoindole derivatives like the CAS no 1159822-61-3 compound may play a role in the treatment of complex diseases requiring multi-target approaches. The ability of this compound to modulate multiple signaling pathways, including PI3K, NF-κB, and PPARγ, makes it a potential candidate for combination therapies. This concept is supported by a 2024 review in Pharmacological Reviews that discusses the advantages of polypharmacology in overcoming drug resistance and improving therapeutic outcomes.

As research into the 5-methoxy-2,3-dihydro-1H-isoindole hydrochloride compound continues to evolve, its potential applications are expanding beyond traditional therapeutic areas. A 2023 study in Advanced Materials explored its use as a molecular probe for imaging applications, leveraging its fluorescent properties. This development highlights the versatility of this compound and its potential to contribute to both therapeutic and diagnostic advancements in medicine.

In conclusion, the CAS no 1159822-61-3 compound represents a compelling example of how molecular structure can influence biological activity. Its diverse pharmacological profiles, coupled with its favorable physicochemical properties, position it as a promising candidate for further investigation. As research methodologies continue to advance, the full therapeutic potential of 5-methoxy-2,3-dihydro-1H-isoindole hydrochloride is likely to become more apparent, opening new avenues for drug discovery and development.

• 739365-33-4(1H-Isoindole,2,3-dihydro-4-methoxy-7-methyl-)
• 5336-62-9(1-(5-methoxy-2-methylphenyl)-N,N-dimethylmethanamine)
• 114041-16-6(5,6-Dimethoxyisoindoline)
• 630407-39-5(2-Methyl-5-methoxyisoindoline)
• 127168-73-4(4-methoxy-2,3-dihydro-1H-isoindole)
• 127168-89-2(2-Benzyl-5-methoxyisoindoline)
• 1203682-51-2(4-Methoxyisoindoline hydrochloride)
• 127168-88-1(5-methoxy-2,3-dihydro-1H-isoindole)
• 1056165-25-3(5-Methoxyisoindoline hydrobromide)
• 356093-22-6(N-(4-Methoxybenzyl)-1-(o-tolyl)methanamine)